Lenograstim

Overview

Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF) that stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropeniaand there by reduce the incidence of associated sepsis; there is yet no evidence thet it improvesoverall survival. I

Categories

Primary Characterstics

Indications

Back to top

Pharmacokinetics

Back to top

Contraindications

Back to top

Drug Interactions

Back to top

Side Effects

The severe or irreversible adverse effects of Lenograstim, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Disturbed hepatic function, Disturbed hepatic function, Anemia, Anemia.

The symptomatic adverse reactions produced by Lenograstim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Hypotension, Bone pain, Vasculitis, Uricemia, Proteinuria, Musculoskeletal pain, Epistaxis.

Back to top

Dosage

Lenograstim's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

150 ug/m2eter150 (150)24 hourlySC,IV InfStarted the day after transplantation /chemotherapy completion.

Paedriatic Dosage (20kg)

19.2 million unit/sq metre35 (35)24 hourlyIV InfusionNot use more than 28 days .Dose recommended for paeds over 2 Yrs
19.2 million/sq metre35 (35)24 hourlySubcutaneousNot use more than 28 days .Dose recommended for paeds over 2 Yrs .

Neonatal Dosage (3kg)

No data regarding the neonatal dosage details of Lenograstim is available.

High Risk Groups

No Information regarding High Risk Group is available.

Back to top

Warning / Precautions

Back to top

Storage Conditions

Inj, Inf

Store in refrigerator.

Back to top

Interference in Pathology

Back to top

Brands / Trade Names of Lenograstim

Back to top

Manufacturers of Lenograstim in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages